Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Addex Therapeutics' Total Current Liabilities rose 4336.82% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 4336.82%. This contributed to the annual value of $911740.4 for FY2024, which is 7169.83% down from last year.
  • Addex Therapeutics' Total Current Liabilities amounted to $1.5 million in Q3 2025, which was up 4336.82% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Addex Therapeutics' Total Current Liabilities peaked at $5.3 million during Q1 2024, and registered a low of $915606.7 during Q4 2024.
  • For the 4-year period, Addex Therapeutics' Total Current Liabilities averaged around $2.7 million, with its median value being $3.0 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 5476.71% in 2024, then tumbled by 7795.79% in 2025.
  • Addex Therapeutics' Total Current Liabilities (Quarter) stood at $3.4 million in 2022, then fell by 4.26% to $3.3 million in 2023, then plummeted by 71.93% to $915606.7 in 2024, then skyrocketed by 60.41% to $1.5 million in 2025.
  • Its Total Current Liabilities was $1.5 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.2 million in Q1 2025.